Long-term survival of patients with glioblastoma multiforme (GBM)
Long-term survival of patients with glioblastoma multiforme (GBM)
复制标题
DOI：
10.1016/j.jocn.2012.05.040
复制
发表时间：
2013-05-01
影响因子：
2
通讯作者：
Gautschi, Oliver P.
中科院分区：
文献类型：
--
作者：
Smoll, Nicolas R.;Schaller, Karl;Gautschi, Oliver P.
在多形性胶质母细胞瘤（GBM）的研究中，长期生存是一个经常使用但定义不清的概念。本研究提出了一种确定GBM患者长期生存时间点的方法。本研究的数据来自监测、流行病学和最终结果数据库，该数据库仅限于使用时间段方法的最新数据。使用相对生存指标，并使用分段恒定危险建立模型来描述GBM长期幸存者的生存概况。对于GBM患者，诊断后第二年（第5个季度）的第一季度被认为是死亡率的高峰，其超额风险比为7.58(95%可信区间= 6.54,8.78)，在诊断后2.5年，GBM的死亡风险降至其死亡率的一半。所有患者的2.5年累积相对生存率（CRS）约为8%，10年的CRS约为2%。使用此处提出的长期生存定义，结果表明长期生存者是指诊断后至少存活2.5年的患者。GBM患者最有可能死亡的时间是诊断后的第5个季度。(c) 2012 Elsevier Ltd.版权所有。
Long-term survival is an often used, yet poorly defined, concept in the study of glioblastoma multiforme (GBM). This study suggests a method to define a time-point for long-term survival in patients with GBM. Data for this study were obtained from the Surveillance, Epidemiology and End-Results database, which was limited to the most recent data using the period approach. Relative survival measures were used and modelled using piecewise constant hazards to describe the survival profile of long-term survivors of GBM. For patients with GBM, the first quarter of the second year (5th quarter) post-diagnosis is considered to be the peak incidence of mortality with an excess hazard ratio of 7.58 (95% confidence interval = 6.54, 8.78) and the risk of death due to GBM decreases to half of its rate at 2.5 years post-diagnosis. The 2.5-year cumulative relative survival (CRS) for all patients is approximately 8%, with a CRS of approximately 2% at 10 years. Using the definition of long-term survival suggested here, the results indicate that long-term survivors are patients who survive at least 2.5 years post-diagnosis. The most likely time period for patients with GBM to die is the 5th quarter post-diagnosis. (c) 2012 Elsevier Ltd. All rights reserved.